AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportTempus AI vs Abridge
Tempus AI
VS
Abridge
Verdict by Category
Detailed Comparison
Feature
Tempus AI
Abridge
Pricing
CustomTempus operates multiple revenue streams with different access models.
Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows.
Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design.
Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.
EnterpriseAbridge does not publish pricing and sells exclusively through enterprise contracts with health systems and hospital groups; there is no self-serve signup or individual-clinician plan. Third-party market analyses and reseller estimates place costs at roughly $200-$800+ per provider per month depending on integration depth (Epic, Oracle Health, or athenahealth), contract scale, and support level, with some estimates for full enterprise rollouts running $600-$1,200+ per provider per month. Implementation typically includes a multi-week to multi-month pilot and IT integration phase before system-wide deployment.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare Tools
Summary
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
Ambient AI that turns clinical conversations into ready-to-sign notes
Tempus AI Pros & Cons
Pros
- Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
- 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
- Comprehensive genomic testing across 6 test types covering all major oncology applications
- Tempus One AI provides real-time clinical insights at the point of care
- TIME Trial dramatically improves clinical trial matching and enrollment rates
- 3,800+ employees and $8.79B total capital raised since founding
- Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease
Cons
- Enterprise and institutional pricing — not accessible to individual clinicians or small practices
- Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
- Genomic test turnaround requires laboratory processing time
- Data platform access and licensing requires formal agreements
- Some AI insights require institutional genomic data infrastructure to fully leverage
Abridge Pros & Cons
Pros
- Best in KLAS for Ambient AI two years running (2025 and 2026)
- Largest independent peer-reviewed study of any ambient AI scribe (NEJM AI, 1,300+ clinicians)
- Deep, native Epic integration across Haiku, Canto, and Hyperdrive
- Broad specialty coverage (55+) across outpatient, inpatient, and ED settings
- Strong enterprise security posture: HIPAA, SOC 2 Type II, ISO 27001
Cons
- No public pricing, free trial, or self-serve signup for individual clinicians
- Enterprise-only sales process that can take months to complete
- Reported documentation error rates (including some hallucinated content) still require clinician review
- No built-in patient communication, scheduling, or billing automation
- Not a realistic option for solo practitioners or small group practices